ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[GTF2I, CCR2]
GO:0006283;transcription-coupled nucleotide-excision repair;9.0;1.0;0.896240625180289;9.628524252492122;184.43692670566384;5.486614186532078;0.006172937954381027;0.676826329833192;[DDB1, AQR, POLR2B, EP300, POLR2G]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[ONECUT2, WBP2, INTS10, ARID4A, HOXC13, POLR2B, TRIM24, ZNF768, EP300, POLR2G, IER2, GTF2I, TBP, NFYC, INTS3, PBX3, ARNT, GRHL1, USF2, FLI1, CDK9, TFCP2, NFIC, TFEC, INTS4, LCOR, TAF7]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[MTPN, TRIM14, CIB1]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CDK9, TBP, POLR2B, NPPA, TAF7, POLR2G, MED6, GTF2I]
GO:0046339;diacylglycerol metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.387362195675234;85.59385656069774;6.943860283624253;0.0028647493496168257;0.7060287030842711;[DGKA]
GO:0007259;JAK-STAT cascade;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;6.221725566191056;8.845336528452411E-4;0.6690987000520388;[IFNAR2, CCR2]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[CCR2]
GO:2000439;positive regulation of monocyte extravasation;10.0;1.0;0.9152410118609203;9.628524252492122;703.5203275945537;9.083926447120524;0.023546192237400974;0.8797934328124444;[CCR2]
GO:0035518;histone H2A monoubiquitination;12.0;0.9326813400603323;0.9144609826203107;9.592156608321247;843.8955673342371;6.8867018697843045;0.028244425181974418;0.8003065664753022;[DDB1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[RIC8A, ALS2, CCM2, EIF4E2, ATP7A, SEC24C]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD244, CCR2]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[TLE4, DDB1, GNG2, CSNK2A1, GNAT2, DVL3, SDC1, SENP2, CALM1, APCDD1]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[NPEPPS, ATP7A, KCNK3]
GO:2000473;positive regulation of hematopoietic stem cell migration;8.0;1.0;0.875;9.628524252492122;201.08518903965808;9.083926447120524;0.006730140312236458;0.839552420951524;[CCR2]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[DEFB1, CALM1, CCR2]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[PRKCSH, DOCK8, DGKA, CLEC16A, ITPR2, IL5RA, DEFB1, KRCC1, BBC3, RAB21, POLB, ABR, NUAK1, GNG2, PABPN1, TIFA, STK38, DVL3, CASP2, EP300, STK38L, NCAM1, RAB8B, CCR2, IFNAR2, IFT122, CNOT10, SETX, ERN1, BCR, CNOT6, SNRK, ITCH, GAL, KARS, ALS2, PTPRA, CNOT1, RAB18, ELMO1, CCM2, CAMK1, DOCK2, CNOT8, CALM1, KPNB1, EXOC1]
GO:0051403;stress-activated MAPK cascade;10.0;0.811012628672052;0.8207473261969463;9.451593544333043;288.8226961090722;5.500407508664414;0.009666635715219814;0.696532107649126;[CCM2]
GO:0070914;UV-damage excision repair;8.0;1.0;0.875;9.628524252492122;251.03601357316452;7.292166977892469;0.008401949456549422;0.747921758369865;[DDB1, HIST3H2A]
GO:1901990;regulation of mitotic cell cycle phase transition;7.0;0.6144040707577935;0.6581214006360973;8.152617732682543;36.34719157774778;3.91914047319701;0.0012165077917585339;0.551344391315166;[ANKRD17, CNOT10, SENP2, ANAPC11, DDB1, CNOT6, CNOT1, TPR, CASP2, EP300, PSME2, ANAPC5, CNOT8, CLASP1, PAFAH1B1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[AHCYL1, SUCNR1, SPHK2, DGKA, DEFB1, IQGAP2, RIC8A, HEBP1, ABR, GNG2, GAL, GNAT2, ADORA3, NPPA, OR56B1, CALM1, CCR2]
GO:0006296;nucleotide-excision repair, DNA incision, 5'-to lesion;8.0;1.0;0.875;9.628524252492122;115.13879119899096;6.166155715036245;0.0038535917232456105;0.6903374900225189;[DDB1]
GO:0090026;positive regulation of monocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;859.35541097108;6.8867018697843045;0.028761852235543582;0.7674272657460779;[CCR2]
GO:0006293;nucleotide-excision repair, preincision complex stabilization;7.0;1.0;0.8509193652572005;9.628524252492122;108.6814430544141;6.7325511899570465;0.003637470092082656;0.6952223462072524;[DDB1]
GO:0090265;positive regulation of immune complex clearance by monocytes and macrophages;6.0;1.0;0.8231203125901445;9.628524252492122;55.8946973761224;9.777073627680469;0.0018707452192170582;0.8231203125901445;[CCR2]
GO:0006294;nucleotide-excision repair, preincision complex assembly;7.0;1.0;0.8509193652572005;9.628524252492122;65.90281547005735;6.409777797693995;0.002205707925099542;0.6787156999164222;[DDB1]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[SUCNR1, KARS, NPPA, CCR2]
GO:0007223;Wnt signaling pathway, calcium modulating pathway;9.0;1.0;0.896240625180289;9.628524252492122;33.206889128170424;6.250713103064308;0.001111404694859899;0.7159023839588838;[GNG2, GNAT2, CALM1]
GO:0043310;negative regulation of eosinophil degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;799.855227739827;9.777073627680469;0.02677043464948191;0.9324289523296623;[CCR2]
GO:0045732;positive regulation of protein catabolic process;7.0;0.7043150770688792;0.7030769037916401;9.033817144745429;231.0521549826792;4.39257856489138;0.0077331076938309705;0.5755560373415389;[DDB1, ITCH, CSNK2A1, ZFAND2A, ATPIF1, VPS11]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[RIC8A, GNG2, GNAT2]
GO:0046549;retinal cone cell development;7.0;1.0;0.8509193652572005;9.628524252492122;36.02440761922304;7.474488534686424;0.0012057045031534136;0.7331650565203278;[GNAT2]
GO:0006654;phosphatidic acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;659.6112576846374;6.139487467954083;0.022076595183113425;0.6889736746265369;[DGKA]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[UBE2I, LRRC29, RNF38, SYVN1, FBXL15, ANAPC11, PSMD8, DDB1, KBTBD4, TRIM9, ITCH, KCTD10, PSMB1, FBXL3, ANAPC5, MAN1B1, RFFL, C18orf25]
GO:0060837;blood vessel endothelial cell differentiation;6.0;0.8653626801206646;0.7558016526504768;9.271849308553389;25.300332287391186;8.16763571524637;8.467793528382013E-4;0.7408135829017477;[CCM2]
GO:0035705;T-helper 17 cell chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;128.70806217747682;9.777073627680469;0.004307743011344492;0.9152410118609203;[CCR2]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CCR2]
GO:0010820;positive regulation of T cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1408.745447987039;7.379178354882098;0.04714944235553481;0.8098004765652196;[CCR2]
GO:0070911;global genome nucleotide-excision repair;9.0;1.0;0.896240625180289;9.628524252492122;184.43692670566384;6.518977089658987;0.006172937954381027;0.7296214167088868;[DDB1]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[WDR48, NDUFS6, TMED2, CCM2]
GO:0007194;negative regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6285.124034700197;6.481236761676141;0.21035744519701882;0.7795710619905949;[CCR2]
GO:0000715;nucleotide-excision repair, DNA damage recognition;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;21.24116723228514;6.641579411751319;7.10922751455178E-4;0.6298916918429109;[DDB1]
GO:0061154;endothelial tube morphogenesis;6.0;0.8259837884571596;0.7361122068187242;9.310070521373587;48.80114014223953;7.379178354882098;0.0016333302423860384;0.7004918368257019;[CCM2]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[SGPL1, CCM2]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[PSMD8, DDB1, PRKCSH, PSMB1, SERPINA10, PSME2, FBXL3, FBXL15, MSLN]
GO:0046834;lipid phosphorylation;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;69.34085176665127;4.948759890378168;0.0023207759059147553;0.5762001235249539;[SPHK2, DGKA]
GO:0001885;endothelial cell development;5.0;0.8259837884571596;0.7032329060895001;9.176539128749065;34.35043118565193;6.444869117505266;0.0011496780184027697;0.6198319182472036;[CCM2]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[ITGB3, CCM2]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[NPEPPS, XPNPEP1, LNPEP]
GO:0046641;positive regulation of alpha-beta T cell proliferation;10.0;0.8653626801206646;0.8479223519212526;9.54628615425515;937.8544877713971;6.8867018697843045;0.03138914569146771;0.7674272657460779;[CCR2]
GO:2000451;positive regulation of CD8-positive, alpha-beta T cell extravasation;12.0;0.8933024483968273;0.8947715367885583;9.55953138100517;875.6996893704704;9.083926447120524;0.029308880524675604;0.9126727335416687;[CCR2]
GO:0045070;positive regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.31211810933421;6.221725566191056;0.0028553198171978322;0.6931793347948383;[DDB1]
GO:0032743;positive regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.409777797693995;0.002183412136085803;0.6509166472493662;[CD4, CCR2]
GO:0042769;DNA damage response, detection of DNA damage;5.0;0.7866048967936545;0.6835434602577475;9.143016436710422;39.83823472227698;6.139487467954083;0.0013333498640710748;0.6042146864874571;[DDB1, WDR48]
GO:0050908;detection of light stimulus involved in visual perception;7.0;1.0;0.8509193652572005;9.628524252492122;116.24341103924905;6.943860283624253;0.003890562355205735;0.7060287030842711;[GNAT2]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[NPEPPS, ITCH, SYVN1, ZFP91, TRIM69, FBXL3, ANAPC5, FBXL15, LNPEP, RFFL, C18orf25, ANAPC11]
GO:1902188;positive regulation of viral release from host cell;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;120.05257821018927;7.069023426578259;0.004018051752389216;0.7365101867784198;[DDB1]
GO:1903238;positive regulation of leukocyte tethering or rolling;10.0;1.0;0.9152410118609203;9.628524252492122;440.9461040801303;8.390779266560578;0.014758069277832396;0.8443458537639685;[CCR2]
GO:0051481;negative regulation of cytosolic calcium ion concentration;11.0;0.9326813400603323;0.8987696223598284;9.57973408832269;290.3013502407617;7.004484905440688;0.00971612493830514;0.7906386361357586;[KCNK3, GTF2I]
GO:0001580;detection of chemical stimulus involved in sensory perception of bitter taste;6.0;1.0;0.8231203125901445;9.628524252492122;24.998545608763582;6.063501560976162;8.36678824294913E-4;0.6332080644001243;[GNAT2]
GO:0007205;protein kinase C-activating G-protein coupled receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.444869117505266;9.028936615729279E-4;0.6527112189764278;[DGKA]
GO:0046726;positive regulation by virus of viral protein levels in host cell;7.0;1.0;0.8509193652572005;9.628524252492122;75.14244873640052;8.390779266560578;0.0025149501353939727;0.7800242071602487;[DDB1]
GO:0007602;phototransduction;6.0;0.811012628672052;0.7286266269261705;9.34084218004034;75.43405895496794;6.039404009397101;0.0025247100669772656;0.6319757144917204;[GNAT2]
GO:1903955;positive regulation of protein targeting to mitochondrion;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;662.5702871444865;6.311337724880743;0.022175631236180954;0.7380031166185408;[NPEPPS, VPS11]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[CD4, GNAT2, ITPR2, CALM1, CCR2]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[CIITA, ONECUT2, ARID4A, OTUD7B, DDX41, HOXC13, AATF, CHD1, YY1, NIPBL, ZMYM2, SAP130, GATAD1, DPF2, ZNF768, EP300, LRRFIP1, ZNF564, IER2, GTF2I, TLE4, TBP, NCOA6, BUD31, SSU72, ZFP91, ARNT, SENP2, ZFX, MED6, TOX4, THAP6, GAL, MTF2, TFEC, LCOR, ZNF394, HDAC3, HDAC1, WBP2, FOXG1, TRAK1, RLF, TPR, SCAP, SUDS3, ZNF189, IRX1, TBX1, ZNF462, DR1, UBE2I, NFYC, PBX3, FBXL15, GRHL1, USF2, FLI1, SOX30, SETX, CDK9, TFCP2, CNOT1, NFIC, SP3, ZNF658, TAF7, CAMK1, ZNF410]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[CCR2]
GO:0048873;homeostasis of number of cells within a tissue;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;26.75021374699733;6.444869117505266;8.953055804826206E-4;0.6527112189764278;[CCR2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[TBX1, BECN1, HDAC3, CSNK2A1, SPHK2, HDAC1, DOCK8, SYVN1, CIB1, AATF, SETX, DDB1, ITCH, CFDP1, SON, PTRH2, NUP62, CASP2, VDAC2, RFFL, SNCB]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[ANKRD17, ITCH, POLR3C, PRDX1, TRIM14, DEFB1, PTX3, RNASE3, SERINC3, CD244, C1QC]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CIB1, CCR2]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[BECN1, WDR48, RNF38, OTUD7B, USP39, PARL, ANAPC11, YY1, SENP6, PSMD8, POLB, VCPIP1, TRIM9, NPEPPS, PSMB1, ADAM23, CASP2, USP51, RFFL, C18orf25, UBE2I, PDCD6IP, LRRC29, RHBDF2, SYVN1, FBXL15, LNPEP, SENP2, DDB1, KBTBD4, ITCH, XPNPEP1, KCTD10, PSME2, FBXL3, ANAPC5, MAN1B1, C1QC]
GO:0002827;positive regulation of T-helper 1 type immune response;8.0;0.8933024483968273;0.8216512241984136;9.503361109538115;171.8650643746189;6.943860283624253;0.005752169036102488;0.7301093378270707;[CCR2]
GO:2000464;positive regulation of astrocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;839.0762499551136;9.777073627680469;0.028083126966399207;0.9152410118609203;[CCR2]
GO:0002829;negative regulation of type 2 immune response;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;108.78588677179087;7.138016298065211;0.0036409657293100133;0.6881587980249038;[CCR2]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176A]
GO:0014886;transition between slow and fast fiber;8.0;1.0;0.875;9.628524252492122;30.57164975977287;9.083926447120524;0.0010232056047610899;0.839552420951524;[GTF2I]
GO:0032897;negative regulation of viral transcription;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;62.48948681665221;6.641579411751319;0.0020914668868664225;0.6905700452391912;[HDAC1, TRIM14]
